United Therapeutics Corporation
UTHRNASDAQHealthcare● Active
$549.87
+$2.18(+0.40%)
Market Cap$23.3B
P/E Ratio—
52W High$609.35
52W Low$272.12
United Therapeutics Corporation (UTHR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
UTHR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$5.82
Est. $7.00 · -16.9%
Revenue
$0.78B
Est. $0.80B · -2.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
UTHR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $7.60B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$7.60B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | $7.17 | — | — | — | $0.81B | — |
| ▼ Q2 FY2026 | May 6, 2026 | $7.00 | $5.82 | -16.9% | $0.78B | $0.80B | -2.0% |
| ▲ Q1 FY2026 | Feb 25, 2026 | $7.13 | $7.70 | +8.0% | $0.79B | $0.81B | -2.8% |
| ▲ Q4 FY2025 | Oct 29, 2025 | $6.89 | $7.16 | +3.9% | $0.80B | $0.81B | -1.9% |
| ▼ Q3 FY2025 | Jul 30, 2025 | $7.29 | $6.41 | -12.1% | $0.80B | $0.80B | -0.4% |
| ▲ Q2 FY2025 | Apr 30, 2025 | $6.29 | $6.63 | +5.4% | $0.79B | $0.78B | +2.0% |
| ▼ Q1 FY2025 | Feb 26, 2025 | $6.40 | $6.19 | -3.3% | $0.74B | $0.73B | +0.2% |
| — Q4 FY2024 | Oct 30, 2024 | $6.43 | $6.39 | -0.6% | $0.75B | $0.72B | +3.6% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
$7.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
$5.82
EPS Est.
$7.00
EPS Surpr.
-16.9%
Revenue
$0.78B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
$7.70
EPS Est.
$7.13
EPS Surpr.
+8.0%
Revenue
$0.79B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
$7.16
EPS Est.
$6.89
EPS Surpr.
+3.9%
Revenue
$0.80B
Q3 FY2025
Jul 30, 2025Miss
EPS Actual
$6.41
EPS Est.
$7.29
EPS Surpr.
-12.1%
Revenue
$0.80B
Q2 FY2025
Apr 30, 2025Beat
EPS Actual
$6.63
EPS Est.
$6.29
EPS Surpr.
+5.4%
Revenue
$0.79B
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
$6.19
EPS Est.
$6.40
EPS Surpr.
-3.3%
Revenue
$0.74B
Q4 FY2024
Oct 30, 2024
EPS Actual
$6.39
EPS Est.
$6.43
EPS Surpr.
-0.6%
Revenue
$0.75B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $7.85 | $8.29 | $9.05 | 3 |
| Q3 FY2027 | $8.02 | $8.46 | $9.24 | 4 |
| Q2 FY2027 | $7.48 | $7.90 | $8.63 | 3 |
| Q1 FY2027 | $7.36 | $7.77 | $8.49 | 3 |
| Q4 FY2026 | $6.92 | $7.31 | $7.98 | 7 |
| Q3 FY2026 | $6.32 | $7.36 | $7.85 | 9 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.9B | $0.9B | $1.0B | 7 |
| Q3 FY2027 | $0.8B | $0.9B | $0.9B | 4 |
| Q2 FY2027 | $0.8B | $0.8B | $0.8B | 6 |
| Q1 FY2027 | $0.7B | $0.8B | $0.8B | 4 |
| Q4 FY2026 | $0.8B | $0.8B | $0.9B | 7 |
| Q3 FY2026 | $0.8B | $0.8B | $0.9B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -16.9% | $572.20 | $596.76 | +4.29% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +8.0% | $473.43 | $535.10 | +13.03% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +3.9% | $415.34 | $455.32 | +9.63% |
| ▼ Q3 FY2025 | Jul 30, 2025 | -12.1% | $297.56 | $281.95 | -5.25% |
| ▲ Q2 FY2025 | Apr 30, 2025 | +5.4% | $300.76 | $303.09 | +0.77% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -3.3% | $357.50 | $318.89 | -10.80% |
| ▲ Q4 FY2024 | Oct 30, 2024 | -0.6% | $352.80 | $361.40 | +2.44% |
| ▼ Q3 FY2024 | Jul 31, 2024 | -8.6% | $337.54 | $313.29 | -7.18% |
Q2 FY2026+4.29%
Report Date
May 6, 2026
EPS Beat/Miss
-16.9%
Price Before
$572.20
Price After
$596.76
Q1 FY2026+13.03%
Report Date
Feb 25, 2026
EPS Beat/Miss
+8.0%
Price Before
$473.43
Price After
$535.10
Q4 FY2025+9.63%
Report Date
Oct 29, 2025
EPS Beat/Miss
+3.9%
Price Before
$415.34
Price After
$455.32
Q3 FY2025-5.25%
Report Date
Jul 30, 2025
EPS Beat/Miss
-12.1%
Price Before
$297.56
Price After
$281.95
Q2 FY2025+0.77%
Report Date
Apr 30, 2025
EPS Beat/Miss
+5.4%
Price Before
$300.76
Price After
$303.09
Q1 FY2025-10.80%
Report Date
Feb 26, 2025
EPS Beat/Miss
-3.3%
Price Before
$357.50
Price After
$318.89
Q4 FY2024+2.44%
Report Date
Oct 30, 2024
EPS Beat/Miss
-0.6%
Price Before
$352.80
Price After
$361.40
Q3 FY2024-7.18%
Report Date
Jul 31, 2024
EPS Beat/Miss
-8.6%
Price Before
$337.54
Price After
$313.29
Avg Beat Reaction+6.47%
Avg Miss Reaction-4.74%
Beat Rate4 / 8 quarters
Largest Move+13.03% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: UTHR ends December
United Therapeutics Corporation (UTHR) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $5.82 — missing the analyst consensus of $7.00 by -16.9%. The next UTHR earnings date is expected around September 1, 2026.
Each quarter, investors track UTHR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. UTHR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
UTHR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
UTHR earnings · 5 questionsUnited Therapeutics Corporation's next earnings report is expected around September 1, 2026. UTHR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; UTHR historically reports after market close (AMC).
UTHR earnings datewhen is UTHR earningsUTHR next earnings datewhen does UTHR report earningsUTHR earnings calendar
▸ Source: FMP · United Therapeutics Corporation SEC filings · US GAAP · United Therapeutics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026